UnknownNot Applicable

Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

Sweden2,500 participantsStarted 2017-11-01

Plain-language summary

To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients fulfilling the RA classification criteria according to the ACR/EULAR Exclusion Criteria: * Patients at stable/unchanged anti-rheumatic treatment * Other serious physical or mental illness * Lack of knowledge in Swedish making answering the questionnaires impossible

What they're measuring

Survivin status

Timeframe: 6 months

Trial details

NCT IDNCT03440892

SponsorVastra Gotaland Region

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2025-01

Contact for this trial

Maria Bokarewa, MD

maria.bokarewa@rheuma.gu.se

View on ClinicalTrials.gov More Rheumatoid Arthritis trials